Novel insights into dendritic cells in the pathogenesis of systemic sclerosis
Open Access
- 13 February 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 201 (1) , 25-33
Abstract
Summary: Systemic sclerosis (SSc) is a severe autoimmune fibrotic disease characterized by fibrosis, vasculopathy, and immune dysregulation. Dendritic cells (DCs) are the most potent antigen-presenting cells, specialized in pathogen sensing, with high capacity to shape the immune responses. The most recent technological advances have allowed the discovery of new DC subsets with potential implications in inflammatory conditions. Alterations of DC distribution in circulation and affected tissue as well as impaired DC function have been described in SSc patients, pointing towards a crucial role of these cells in SSc pathogenesis. In particular, recent studies have shown the importance of plasmacytoid DCs either by their high capacity to produce type I interferon or other inflammatory mediators implicated in SSc pathology, such as chemokine C-X-C motif ligand 4 (CXCL4). In-vivo models of SSc have been vital to clarify the implications of DCs in this disease, especially DCs depletion and specific gene knock-down studies. This review provides these new insights into the contribution of the different DCs subsets in the pathogenesis of SSc, as well as to the novel developments on DCs in in-vivo models of SSc and the potential use of DCs and their mediators as therapeutic targets.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (93526/2013)
This publication has 82 references indexed in Scilit:
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trialThe Lancet, 2013
- Arsenic Trioxide Prevents Murine Sclerodermatous Graft-versus-Host DiseaseThe Journal of Immunology, 2012
- Increased serum levels of soluble CD163 in patients with sclerodermaClinical Rheumatology, 2012
- A one‐year, phase I/IIa, open‐label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung diseaseArthritis & Rheumatism, 2011
- Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosisAnnals of the Rheumatic Diseases, 2010
- Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosisArthritis Research & Therapy, 2010
- Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: Evidence of possible gene–gene interaction and alterations in Th1/Th2 cytokinesArthritis & Rheumatism, 2009
- STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosisArthritis & Rheumatism, 2009
- Association of a functional polymorphism in the IRF5 region with systemic sclerosis in a Japanese populationArthritis & Rheumatism, 2009
- Animal Model of Sclerotic Skin. I: Local Injections of Bleomycin Induce Sclerotic Skin Mimicking SclerodermaJournal of Investigative Dermatology, 1999